Symposium: Microbiome in Human Disease
Human microbiota, the collection of microorganisms living inside and on the surface of our bodies, have been associated with various aspects of numerous diseases. These associations include susceptibility, causation, complications, and even prevention. While the impact of translational microbiological research, most dramatically in the cure and prophylaxis of infectious diseases, has been extraordinary, the relationship of the microbiome to other disease states remains under investigated, as does the import of microbial ecology in normal and pathological states.
The Microbiome in Human Disease Symposium, sponsored by the Harvard Catalyst Reactor Program, will provide researchers with the opportunity to learn about current human microbiome research and promote a greater understanding of the role(s) microbiomes play in the manifestation and treatment of human disease in its broadest sense. Information about many of the microbiome-related cores and services from across the university and hospitals will be highlighted.
- Ashwin Ananthakrishnan, MBBS, MPH, Massachusetts General Hospital
- Emily Balskus, PhD, Harvard University
- C. Ronald Kahn, MD, Joslin Diabetes Center
- Matthew Meyerson, MD, PhD, Dana-Farber Cancer Institute
- Hera Vlamakis, PhD, Broad Institute
- Howard L. Weiner, MD, Brigham and Women’s Hospital
An announcement will be made during the symposium about an upcoming funding opportunity that focuses on the role(s) microbiomes play in the manifestation and treatment of human disease in its broadest sense.